HC Wainwright & Co. Downgrades Iterum Therapeutics to Neutral

HC Wainwright & Co. analyst Matthew Keller has downgraded Iterum Therapeutics (NASDAQ: ITRM) from a 'Buy' rating to 'Neutral'. This change reflects a shift in the analyst's outlook on the company's performance.